Table 1.
Characteristics of the 140 included patients
| Characteristic | ||
|---|---|---|
|
Age (years) |
|
|
| Median |
70 |
|
| Mean |
69 |
|
| Range |
45–83 |
|
|
Median follow-up (months) |
58.3 |
|
| |
Number |
% |
|
Race |
|
|
| White |
125 |
89.3 |
| Black |
5 |
3.6 |
| Other |
10 |
7.1 |
|
T Stage |
|
|
| T1a |
5 |
3.6 |
| T1b |
3 |
2.1 |
| T1c |
65 |
46.5 |
| T2a |
51 |
36.4 |
| T2b |
8 |
5.7 |
| T2c |
3 |
2.1 |
| T3a |
4 |
2.9 |
| T3b |
1 |
0.7 |
|
Gleason score |
|
|
| ≤ 6 |
53 |
38 |
| 7 |
56 |
40 |
| 8 – 10 |
31 |
22 |
|
PSA |
|
|
| < 10 |
106 |
75.7 |
| 10 – 19.9 |
28 |
20 |
| >20 |
6 |
4.3 |
|
NCCN Risk Group |
|
|
| Low |
36 |
25.7 |
| Intermediate |
64 |
45.7 |
| High |
40 |
28.6 |
|
Prescribed dose levels (Gy) |
|
|
| 74 |
18 |
13 |
| 76 |
20 |
14 |
| 78 |
50 |
36 |
| 80 | 52 | 37 |